Eli Lilly plans to make tirzepatide next big thing as pharma experiences 'unprecedented' demand for the drug
Eli Lilly has been pushing forward on its plans to expand tirzepatide into a megablockbuster, and while the Big Pharma is touting an increase in sales compared to previous quarters, it is trimming down its year-end guidance.
The Big Pharma reported $6.94 billion in Q3 revenue, better than expected compared to the $6.49 billion reported last quarter and the $6.7 billion Lilly reported in Q3 last year. Part of that is thanks to higher than expected sales of Mounjaro (tirzepatide), Lilly’s type 2 diabetes drug that was just approved by the FDA earlier this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
